 Acorda Therapeutics Inc NASDAQ:ACOR has provided long-term financial guidance and an updated business plan in preparation for the special meeting of its stockholders this week, and updated its net revenue forecast from US116 million to 121 million in 2023, and as much as 199 million by 2027. The Pearl River, New York-based company said it expects to increase the market for two of its pharmaceuticals Inbrija for patients with Parkinsons disease, and Ampyra, used to treat adults with multiple sclerosis. 